Abbisko Therapeutics’ CD73 Inhibitor ABSK051 Clears for Phase I Clinical Trial in China
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
Cancer
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...
Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC
Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report...
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...
Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...
Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...
Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Zhejiang Huahai Pharmaceutical’s HB0052 Receives US FDA IND Approval for Solid Tumors
IntroductionZhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...
BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE
The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab)...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has...
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the...
Gaush Meditech Ltd Receives NMPA Approval for Rigid Corneal Contact Lens
Gaush Meditech Ltd (HKG: 2407), a company based in Suzhou, has announced that it has...
Amoy Diagnostics Receives NMPA Approval for MSI Detection Kit as Companion Diagnostic for Immunotherapy
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in the Chinese diagnostics industry,...
Wuhan Hiteck Biological Pharma Receives NMPA Approval for Aponermin in Multiple Myeloma Treatment
Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that...